Regulatory News:

ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announces its financial calendar for 2024.

Events

Dates*

2023 Full-Year Results

Monday, March 11, 2024

Cash position and activity update for Q1 2024

Thursday, May 16, 2024

Cash position and activity update for Q2 2024

Thursday, August 22, 2024

2024 Half-Year Results

Thursday, September 26, 2024

Cash position and activity update for Q3 2024

Thursday, November 14, 2024

* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines in diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I -based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in sepsis and critical care.

NewCap Investor relations Nicolas Fossiez Louis-Victor Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53 NewCap Media relations Arthur Rouillé abionyx@newcap.eu +33 (0)1 44 71 00 15

Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024 Plus de graphiques de la Bourse Abionyx Pharma
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024 Plus de graphiques de la Bourse Abionyx Pharma